NeuroOne Medical Technologies (NASDAQ:NMTC) Rating Increased to Strong-Buy at Zacks Research

NeuroOne Medical Technologies (NASDAQ:NMTC) was upgraded by investment analysts at Zacks Research from a “hold” rating to a “strong-buy” rating in a research note issued to investors on Monday,Zacks.com reports.

Several other research analysts have also recently weighed in on NMTC. Maxim Group assumed coverage on shares of NeuroOne Medical Technologies in a report on Tuesday, September 9th. They issued a “buy” rating and a $3.00 price target for the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of NeuroOne Medical Technologies in a research report on Wednesday, October 8th. Finally, Wall Street Zen upgraded NeuroOne Medical Technologies to a “hold” rating in a report on Friday, October 3rd. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $2.23.

NeuroOne Medical Technologies Price Performance

NASDAQ NMTC opened at $0.98 on Monday. NeuroOne Medical Technologies has a one year low of $0.40 and a one year high of $1.39. The firm has a market cap of $49.43 million, a P/E ratio of -12.26 and a beta of 0.70. The stock’s 50-day moving average is $0.71 and its 200-day moving average is $0.78.

NeuroOne Medical Technologies (NASDAQ:NMTC) last issued its quarterly earnings data on Tuesday, December 16th. The company reported $0.04 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.04) by $0.08. NeuroOne Medical Technologies had a negative return on equity of 74.69% and a negative net margin of 29.81%.The business had revenue of $2.74 million during the quarter, compared to analyst estimates of $2.47 million. During the same period in the previous year, the firm earned ($0.46) EPS.

Hedge Funds Weigh In On NeuroOne Medical Technologies

A number of large investors have recently modified their holdings of NMTC. Focus Financial Network Inc. bought a new position in shares of NeuroOne Medical Technologies in the 3rd quarter valued at about $31,000. Warberg Asset Management LLC acquired a new position in shares of NeuroOne Medical Technologies during the 2nd quarter worth approximately $27,000. Susquehanna International Group LLP acquired a new position in shares of NeuroOne Medical Technologies during the 3rd quarter worth approximately $47,000. XTX Topco Ltd acquired a new position in shares of NeuroOne Medical Technologies during the 2nd quarter worth approximately $51,000. Finally, Goldman Sachs Group Inc. bought a new stake in shares of NeuroOne Medical Technologies during the 1st quarter worth approximately $84,000. 16.07% of the stock is currently owned by institutional investors and hedge funds.

About NeuroOne Medical Technologies

NeuroOne Medical Technologies Corp. is a medical device company focused on developing advanced neural interface technologies for diagnostic and therapeutic applications in neurosurgery and neurology. The company’s core mission is to improve patient outcomes through next-generation electrode systems that enable high-resolution neural recording and targeted stimulation. By leveraging proprietary thin-film microelectrode arrays, NeuroOne aims to offer clinicians unprecedented single-unit precision during brain mapping procedures.

The company’s flagship platform, the EVO™ system, integrates thin-film neural electrodes with intraoperative monitoring hardware and software.